What is the level of liabilities of Equillium this year?
Equillium has a debt balance of 27.96 M USD this year.
Equillium Liabilities 2025
Equillium Liabilities
27.96 M USD
Ticker
EQ
ISIN
US29446K1060
WKN
A2N7B3
In 2025, Equillium's total liabilities amounted to 27.96 M USD, a -39.85% difference from the 46.48 M USD total liabilities in the previous year.
Equillium Aktienanalyse
What does Equillium do?
Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Equillium's Liabilities
Equillium's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Equillium's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Equillium's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Equillium's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Equillium’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Equillium stock
What were the liabilities of Equillium compared to the previous year?
The liabilities of Equillium have increased by -39.85% dropped compared to the previous year.
What are the consequences of high debt for investors of Equillium?
High liabilities can pose a risk for investors of Equillium, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Equillium?
Low liabilities mean that Equillium has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Equillium affect the company?
An increase in liabilities of Equillium can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Equillium affect the company?
A decrease in the liabilities of Equillium can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Equillium?
Some factors that can influence the liabilities of Equillium include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Equillium so important for investors?
The liabilities of Equillium are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Equillium take to modify the liabilities?
To change its liabilities, Equillium can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Equillium pay?
Over the past 12 months, Equillium paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Equillium is expected to pay a dividend of 0 USD.
What is the dividend yield of Equillium?
The current dividend yield of Equillium is .
When does Equillium pay dividends?
Equillium pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Equillium?
Equillium paid dividends every year for the past 0 years.
What is the dividend of Equillium?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Equillium located?
Equillium is assigned to the 'Health' sector.
Wann musste ich die Aktien von Equillium kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Equillium from 2/13/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/13/2025.
When did Equillium pay the last dividend?
The last dividend was paid out on 2/13/2025.
What was the dividend of Equillium in the year 2024?
In the year 2024, Equillium distributed 0 USD as dividends.
In which currency does Equillium pay out the dividend?
The dividends of Equillium are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Equillium
Our stock analysis for Equillium Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Equillium Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
